

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	16/773,641
				Filing Date	January 27, 2020
				First Named Inventor	John Maloney
				Art Unit	1612
				Examiner Name	Benjamin J. Packard
Sheet	1	of	1	Attorney Docket Number	066859/543316

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	235	Declaration of John Geissler, Exhibit 1, Response in Opposition to Plaintiff's Motion for Preliminary Injunction, Exela Pharma Sciences, LLC v.Sandoz, Inc., No. 1:19-cv-318, (W.D.N.C., December 6, 2019).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

LEGAL02/39734152v1

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	39191199
<b>Application Number:</b>	16773641
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3992
<b>Title of Invention:</b>	STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE
<b>First Named Inventor/Applicant Name:</b>	John Maloney
<b>Customer Number:</b>	826
<b>Filer:</b>	Bryan Lee Skelton/Laura Tremont
<b>Filer Authorized By:</b>	Bryan Lee Skelton
<b>Attorney Docket Number:</b>	066859/543316
<b>Receipt Date:</b>	17-APR-2020
<b>Filing Date:</b>	27-JAN-2020
<b>Time Stamp:</b>	14:07:28
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	543316_IDS_Transmittal.pdf	138271 0ef7fa5eb522189e3b2c64ee8298897be7dca8b	no	1

**Warnings:**

Information:					
2	Information Disclosure Statement (IDS) Form (SB08)	543316_IDS_SB08.pdf	160712 74528352c973a489a55d0efd74c943ab5ac3ef26	no	1
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Non Patent Literature	235-Declaration_of_John_Geissler.pdf	11773346 a67540046560cc46bc60cb397161350d9b405938	no	53
Warnings:					
Information:					
Total Files Size (in bytes):			12072329		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: John Maloney et al. Confirmation No.: 3992  
Appl. No.: 16/773,641 Group Art Unit: 1612  
Filed: January 27, 2020 Examiner: Benjamin J. Packard  
For: STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION  
AND METHODS OF USE

Submitted via EFS-Web  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
CITATION UNDER 37 C.F.R. § 1.97**

Attached is a list of documents on form PTO-SB08.

Submitted herewith is the Declaration of John Geissler and its Exhibits A-F, submitted in concurrent litigation, *Exela Pharma Sciences, LLC v. Sandoz, Inc.*, No. 1:19-cv-318, (W.D.N.C., November 6, 2019), which was referred to in Applicant's previous Information Disclosure Statement. Applicant points the Examiner's attention to the batch data on page 45 of 53.

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By identifying the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead identifying the listed documents for the sake of full disclosure.

Respectfully submitted,

/bryan l. skelton/

Bryan L. Skelton  
Registration No. 50,893

**Customer No. 826**  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Research Triangle Area Office (919) 862-2200  
Fax Research Triangle Area Office (919) 862-2260

**ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON April 17, 2020.**

LEGAL02/39734159v1